Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions about its new laboratory in Las Vegas, and its recently refiled S1 with the SEC, in an interview of Matthew Schissler, founder and CEO, by analyst Francis Gaskins.
The entire interview is available at http://www.stoxrox.com/cbai-11-5-09.mp3
In the interview Mr. Schissler said:
- The S1 registration statement withdraws an earlier filing, saves the Company money, and will not be used until necessary.
- The new Las Vegas lab reduces costs because lab services will no longer be outsourced.
- This subsequently will increase gross profits for the Company and its shareholders.
- The new lab increases the Company's revenue streams, with significant new opportunities to store other biological products and other lines of stem cells including stem cells from other companies.
- Finally the new lab gives Cord Blood America the opportunity to work with other stem cell companies in research and development.
Red light therapy shown to significantly reduce blood sugar spikes, study finds